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Abstract
Since the publication of the National Lung Screening Trial (NLST) showing a mortality reduction with use of low-
dose computed tomography (LDCT), there has been considerable interest about the use of this modality to screen for 
lung cancer. This article reviews the NLST and the current evidence behind screening for lung cancer in smokers. 
It also attempts to look at different lung cancer risk models to help better define the ideal target population and last 
touches on the cost-effectiveness of LDCT screening in patients at high risk of lung cancer.
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2 and year 3 versus regular care. Patients were followed 
for 13 years or till 31st December, 2009, whichever were 
earlier. The investigators found no mortality benefit of 
using chest X-rays to screen for lung cancer.
At the same time, interest had begun to develop on the 
use of low-dose computed tomography (LDCT). In the 
1990s and 2000s, uncontrolled studies using LDCTs 
demonstrated that more lung cancers, specifically more 
Stage I cancers, could be identified using annual LDCT 
screening.[5-8] However, none of these studies was able 
to demonstrate a morality benefit of using annual LDCT 
scans to screen for lung cancer. It was felt that perhaps 
these studies were underpowered to demonstrate such 
an effect. In light of this encouraging data, a larger trial 
called ‘The National Lung Screening Trial’ (NLST) was 
conducted in the United States.[9]
NLST
The NLST involved 53,454 individuals from 33 centres 
who were randomised from 2002 till 2004 to receive 
annual LDCT or CXR. This number was deemed 
necessary to indicate a 21% reduction in mortality with a 
power of 90%. To be eligible for the trial, an individual 
had to be between 55 and 74 years of age at the time of 
randomisation, has a history of cigarette smoking of at 
least 30 pack-years and, if a former smoker, has to quit 
within the previous 15 years. Participants underwent three 
screenings at baseline, year 1 and year 2.
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Introduction
Lung cancer is an important tobacco-related malignancy 
globally accounting for an estimated 1.3 million deaths 
per year, which represents 28% of all cancer-related 
deaths.[1] In 2015, lung cancer incidence rates in Pakistan 
were the third highest after breast cancer and lip and 
oral cavity cancer. However, it accounted for the second 
highest number of cancer deaths after breast cancer.[2] 
In light of the significant health-care costs and mortality 
associated with this malignancy, efforts have been 
made to develop adequate screening tools for the early 
detection of lung cancer. This article will attempt to 
briefly look at the current evidence and recommendations 
regarding lung cancer screening in the current or former 
smokers.
Background
Initial efforts at developing a screening tool for the 
detection of lung cancer centred on using chest radiography 
(CXR). The early studies did not show any morality benefit 
of using CXRs as a screening tool for lung cancer,[3] a 
fact that was confirmed in 2011 with the publication 
of the Prostate, Lung, Colorectal and Ovarian (PLCO) 
trial.[4] The investigators randomised 154,901 patients to 
receive four screening CXRs at baseline, year 1 and year 
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Any non-calcified lung nodule > 4 mm in diameter was 
considered ‘screen positive’ as was any evidence of a 
pleural effusion or lymphadenopathy. These patients were 
then investigated further. As a result of these criteria, the 
proportion of screen positives was high at 24.9% in the 
LDCT group versus 6.9% in the control group (CXR 
group).
The lung cancer detection rates in the study and control 
groups were 645 and 572/100,000 person-years, 
respectively. The lung cancer mortality rates in the study 
and control groups were 247 and 309/100,000 person-
years, respectively. Both of these changes were significant 
and there was an effective 20% reduction in lung cancer-
related mortality rate in the LDCT group (P = 0.004).[9]
The investigators determined that 320 participants would 
need to be screened to see a decrease of one death from 
lung cancer. In other words, the absolute risk of lung 
cancer deaths was reduced from 1.66% to 1.33%, or 
three fewer deaths per 1000 participants screened in the 
LDCT arm. Of note, the study was terminated early after 
an independent data and safety board determined that the 
primary end point had been met.
The results of another randomised trial entitled the 
‘Netherlands-Leuven Longkanker Screening Network’ 
trial involving 15,822 participants are still awaited and 
have not yet been published.[10] Based on the results of the 
NLST in 2013, the U.S Preventive Services Task Force 
recommended annual screening for lung cancer with 
LDCT in adults aged 55–80 years of age who have a 30 
pack-year smoking history and currently smoke or have 
quit within the past 15 years. They stated that screening 
should be discontinued once a person has not smoked 
for 15 years or develops a health problem that limits life 
expectancy or the ability or willingness to curative lung 
surgery.[11]
Rationale for using lung cancer risk stratification 
tools
Although the NLST did show a survival advantage, it 
was also associated with a high number of false positives. 
In an attempt to better refine these criteria, Kovalchik 
et al.[12] developed a prediction model for lung cancer 
deaths. The selected risk factors for their prediction 
model included age, body mass index, family history of 
lung cancer, pack-years of smoking, years since smoking 
cessation and emphysema diagnosis. They created five 
quintiles of patients who were divided according to their 
risk of lung cancer. The 5-year risk of lung cancer was as 
follows: 0.15–0.55% in quintile 1, 0.56–0.84% in quintile 
2, 0.85–1.23% in quintile 3, 1.24–2.00% in quintile 4 
and >2.00% in quintile 5. They observed that 60% of 
participants at highest risk for lung cancer deaths (quintile 
3 through 5) accounted for 88% of the screening-prevented 
lung cancer deaths, while the 20% of participants at lowest 
risk (quintile 1) accounted for only 1% of prevented lung 
cancer deaths. Their findings led support to the idea of 
risk-based targeting of smokers.
Similarly, Tammemägi et al.[13] developed a validated 
model (PLCO M2012) with data from the PLCO control and 
intervention groups who ever smoked. They compared 
the accuracy of PLCO M2012 criteria with NLST criteria. 
Their criteria included age, level of education, body mass 
index, family history of lung cancer, chronic obstructive 
pulmonary disease, CXR in the previous 3 years, smoking 
status, history of smoking and quit time. They noted that 
as compared to NLST, PLCO M2012 had more sensitivity 
(83% vs. 71% P < 0.001) and positive predictive value 
(4.0% vs. 3.4% P = 0.01), without loss of specificity 
(62.9% vs. 62.7% P = 0.54). Furthermore, 41.3% fewer 
lung cancers were missed.
Another simpler approach was taken by Sanchez-Salcedo 
et al.[14] when they applied NLST criteria in two different 
lung cancer screening studies from the United States and 
Europe. They noted that 36% and 59% of participants 
in the two studies, respectively, met NLST criteria. 
Although applying the NLST criteria alone would have 
missed 39% of all lung cancers, the addition of ‘presence 
of emphysema’ or ‘meeting NLST criteria’ resulted in 
detection of most lung cancers (95% in the United States 
study and 88% in the European study).
Lung cancer amongst light or never smokers
Another issue that has been raised by researchers is the 
emphasis on heavy current and former smokers in the 
NLST. Pinsky and Berg[15] noted that when NLST criteria 
were applied to data from the Surveillance, Epidemiology 
and End Results, the 2010 census and the National Health 
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Interview Survey, only 27% of patients with lung cancer 
would have been eligible for screening. This suggests that 
a large portion of people who develop lung cancer are 
being missed by application of NLST criteria. When the 
authors applied a broader age range and lower smoking 
threshold, they were able to capture 68% of all lung 
cancers.
The issue of lung cancer in light or never smokers 
becomes even more important when looking at a non-
Caucasian population since 90% of participants in NLST 
were Caucasian. Studies from Japan have suggested a 
higher proportion of lung cancer amongst women and 
also amongst light or never smokers in their population 
when compared to western populations.[16] At present, a 
randomised control trial on non-/light smokers is being 
conducted in Japan.[17] Once the results of this trial are 
available, more can be deduced on the efficacy of LDCT 
screening in non-/light non-Caucasian smokers.
Until more is known from trial data, there is no 
recommendation to screen patients who are light smokers; 
however, on an individual basis, physicians may want to 
consider patients with emphysema and/or a strong family 
history of lung cancer.
Assessing the costs
The NLST estimated its cost-effectiveness (CT vs. chest 
X-ray) at $52,000 per life year gained and $81,000 per 
quality-adjusted life year gained.[18] Other systemic 
reviews indicated the cost-effectiveness estimates for 
LDCT screening for lung cancer range of $18,452–
$66,480 per life year gained.[19-20] These numbers are 
acceptable in the United States where a threshold of 
$100,000 is considered acceptable; however, the cost 
may be prohibitive in the third world or some European 
countries. According to the World Health Organisation, 
an intervention that costs <3 times the national annual 
per capita gross domestic product is considered cost-
effective.[21] In light of the costs entailed, including the 
potential harms such as; the high false positive rate found 
in the NLST individual countries would be advised to first 
assess the prevalence of lung cancer in their population 
amongst different age groups before developing a country-
specific lung cancer risk model. Such an approach may 
be a more fiscally responsible one.
Conclusion
The NLST has clearly demonstrated a 20% reduction in 
lung cancer mortality when LDCT screening is used for 
heavy current or former smokers. In the absence of other 
data, the physician may use NLST criteria for lung cancer 
screening. Alternatively, application of a lung cancer 
risk assessment model may allow for more rational use 
of resources. For individual countries, the development 
of national cancer databases is imperative to better apply 
LDCT screening for smokers depending on how lung 
cancer presents in their particular populations.
Finally, the results of the above-mentioned studies are still 
awaited and will continue to shed more light on the issue 
of lung cancer screening with LDCT.
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